drug and alcohol-free workplace program<\/strong><\/a> and gives employees the information they need to get help when needed and maximize their benefit from a program. Active employee education plans should provide company-specific knowledge, such as the details of the company’s policy, as well as comprehensive knowledge of the nature of drug or alcohol addiction; its impact on work performance, health, and personal life. All employees should have ready access to this information and it should be available on an ongoing basis through a variety of delivery methods.<\/p>\n\n\n\nRandom testing is not enough by itself; reasonable suspicion drug testing is also critical as is supervisor training. A manager or supervisor who has not had sound reasonable suspicion training may not be able to properly recognize and document specific behaviors, appearance, attitude changes, and more that would warrant a reasonable suspicion test. Many supervisors also confuse random and reasonable suspicion testing which could open your company up to legal issues and liability.<\/p>\n\n\n\n
The laws vary, sometimes greatly, from state to state so it is essential to know what laws that affect your business or you can work with a TPA (Third Party Administrator) that can assist you in making the best decisions in regards to your Drug and Alcohol Testing Program and implementation.<\/p>\n\n\n\n
Check out our blog for other great articles and information on topics like marijuana legalization, the intoxication defense to defend against a workers\u2019 compensation claim, workers compensation premium discounts for a drug free workplace and much more.<\/p>\n","protected":false},"excerpt":{"rendered":"
Department of Labor reported that the abuse of drugs and alcohol in the workplace, cause 65 percent of accidents and 38 percent to 50 percent of the claims of all employees associated with alcohol or drug abuse in the workplace. Drug testing programs are a powerful deterrent to drug and alcohol use in the workplace […]<\/p>\n","protected":false},"author":12,"featured_media":52326,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"51535,51391,50935,50930,50870,50901","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51047"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51047"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51047\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/52326"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}